Ads
related to: multiple myeloma progression free survival rate- Treatment Schedule
Learn How This Treatment Is Given
Find Out About Infusion Times
- How Treatment Works
Watch a Video
On How This Therapy Works
- Treatment Homepage
Find the Latest Information
On This Treatment
- Treatment Resources
Get Resources and Treatment Info
For Patients and Caregivers
- Treatment Schedule
Search results
Results From The WOW.Com Content Network
MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.
In this study, ixazomib increased the median time of progression-free survival from 14.7 months (in the placebo+lenalidomide+dexamethasone study arm including 362 people) to 20.6 months (under ixazomib+lenalidomide+dexamethasone, 360 people), which was a statistically significant effect (p = 0.012). 11.7% of patients in the ixazomib group had a ...
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.
Multiple myeloma is usually diagnosed because malignant plasma cells continue to produce an ... the Mayo Clinic reported progression-free survival rates of 98%, 94% ...
Eligible patients were required to have relapsed refractory multiple myeloma. [6] Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity. [6]
Solubilized BCMA can sequester BAFF, preventing it from signaling B cells, resulting in reduced polyclonal antibody levels in patients with MM. [16] In multiple studies, sBCMA levels have been found to correlate with the severity of myeloma. Notably, sBCMA levels are predictive of response to therapy, PFS and OS.
Ads
related to: multiple myeloma progression free survival rate